Imbruvica

Ibrutinib, the active ingredient in Imbruvica, is a Bruton’s tyrosine kinase (BTK) inhibitor presented as an oral capsule for adult patients. It is used to treat several B‑cell malignancies, including chronic lymphocytic leukemia, mantle‑cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, and chronic graft‑versus‑host disease, and is approved in the European Union.

GNH USA supplies Imbruvica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imbruvica targets B‑cell receptor signaling pathways and is indicated for several hematologic malignancies and immune‑mediated conditions.

- Chronic lymphocytic leukemia: improves progression‑free and overall survival in adult patients. - Mantle cell lymphoma: used in combination therapy for relapsed or refractory disease. - Waldenström macroglobulinemia: reduces disease activity and serum IgM levels. - Marginal zone lymphoma: provides disease control in patients unsuitable for chemotherapy. - Chronic graft‑versus‑host disease: mitigates symptoms in adults with steroid‑refractory disease.

Ibrutinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: loose stools that may be mild to moderate. - Nausea: occasional upset stomach or feeling of queasiness. - Fatigue: generalized tiredness affecting daily activities. - Bruising or mild bleeding: easy bruising or nosebleeds. - Rash: skin irritation or erythema. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Atrial fibrillation: new‑onset irregular heart rhythm. - Infections: opportunistic or serious bacterial infections. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Severe neutropenia: markedly low white‑blood‑cell count. - Hepatic toxicity: elevated liver enzymes or liver injury.

When prescribing Imbruvica, clinicians should observe several precautionary measures to minimize risks.

- Monitor blood counts: perform regular CBC tests to detect cytopenias. - Assess bleeding risk: evaluate concomitant anticoagulant use and history of hemorrhage. - Cardiac monitoring: observe for new‑onset atrial fibrillation or arrhythmias. - Infection surveillance: watch for signs of opportunistic or severe infections. - Hepatic function: check liver enzymes periodically. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and light.

Ibrutinib is metabolized primarily by CYP3A4, making it susceptible to drug‑drug interactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ibrutinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug levels. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increase risk of serious bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, diltiazem): may require dose adjustment. - Antifungal agents with CYP3A activity (e.g., voriconazole): monitor for enhanced effects. - Proton pump inhibitors: may affect absorption; observe therapeutic response.